Tag: pharmaceuticals

  • Private Equity Company Founds $50M Biologics Start-Up

    Celtic Therapeutics, a private equity company in the U.S. and Europe, has started a new company to bring to market therapies based on antibody drug conjugates (ADCs) that bind to and kill cells with the targeted properties. The new company, known as ADC Therapeutics and based in Lausanne, Switzerland will have an initial investment of…

  • Trial Underway for Non-Addictive ADHD Drug for Adults

    Euthymics Bioscience Inc. in Cambridge, Massachusetts says it has started a phase 1 clinical trial of its drug candidate EB-1020 to treat attention deficit hyperactivity disorder (ADHD) in adults. The company says that EB-1020 is notable because it has a low risk of drug abuse liability, a problem with some current drugs for ADHD that…

  • GSK, Johnson & Johnson Join in Life Science Venture Fund

    The London-based venture capital company Index Ventures unveiled a new investment fund for early-stage life sciences companies, with pharmaceutical companies GlaxoSmithKline and Janssen, a division of Johnson & Johnson, among the investors. The Index Life VI fund, valued at €150 million ($US230 million), is the first for Index Ventures devoted solely to the life sciences.…

  • Unilever Launches Open Innovation Initiative

    The consumer goods manufacturer Unilever unveiled today its open innovation program seeking ideas for new products and technologies from the public at large. The initiative is managed by the online intellectual property marketplace yet2.com. Unilever’s program is structured around a set of issues or problems for which it seeks collaborators to find solutions. The opening…

  • European Autism Research Consortium Launched

    An international coalition of pharmaceutical companies, universities, and advocacy organizations aims to discover new drugs to battle autism spectrum disorder, a collection of conditions affecting social interaction and communication. The project known as European Autism Interventions: A Multicentre Study for Developing New Medications (EU-AIMS) is considered the largest single grant for autism research in the…

  • Osteoporosis Drug Developer Secures $28M in Series B Round

    Tarsa Therapeutics Inc., a Philadelphia-based developer of drugs to treat osteoporosis, has completed $28 million in new series B financing, the second round of funding after initial start-up. The financing package, announced on Friday, is led by a new investor in the company, Foresite Capital. The funding is expected to support the next commercialization and…

  • Tracking Antibiotic Use Reaps Big Hospital Cost Savings

    Analysis of a program to monitor unnecessary use of antibiotics shows the program saved one big-city hospital millions of dollars without compromising patient care. That’s the conclusion of a study done by researchers at University of Maryland Medical Center (UMMC) in Baltimore, where, the study was conducted, as well as colleagues from hospitals in Wilmington,…

  • Merck to Fund New Translational Research Institute

    The pharmaceutical company Merck in Whitehouse Station, New Jersey unveiled plans today to establish the California Institute for Biomedical Research (Calibr), an independent, not-for-profit organization to speed the translation of basic biomedical research into new medicines to treat disease. Merck is expected to provide up to $90 million financing for Calibr over seven years. Researchers…

  • Algorithm Mines FDA Reports for Drug Interactions

    Researchers at Stanford University’s medical school and bioengineering program have devised a computer algorithm that can query millions of adverse drug reports to the U.S. Food and Drug Administration (FDA) by patients and their physicians, and identify many more drug interactions and side effects than were previously known. Their work is described in the journal…

  • Biotech Secures $13M in Series B Funding for Clinical Trial

    HemaQuest Pharmaceuticals Inc., a biotechnology company in San Diego, closed a $13 million extension of its series B financing, the second round of funding after initial start-up. The extension is funded by existing investors Aberdare Ventures, De Novo Ventures, Forward Ventures, Latterell Venture Partners, and Lilly Ventures. HemaQuest develops small molecule therapies to treat disorders…